Annual General Meeting and Update on Trading

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, will hold its Annual General Meeting at 11.00 today.

Dr. Don Evans, Non-Executive Chairman of the Group, will make the following statement regarding current trading.

"I am pleased to report that the good start to the year, as highlighted in the 2011 Preliminary Results announcement on 7 March 2012, is continuing.

We continue to make good progress in the US market with our LiquiBand® range of products, with end-user sales increasing and further market share gains. We expect to see the impact of this progress in our ex-factory sales during the second half and we anticipate good growth for the full year. In relation to LiquiBand Flex®, we are well advanced with signing up and training distributors and are currently going through key evaluations which should be finalised by the end of the summer.

Our integration of RESORBA® is progressing to plan. We are advancing through the programme set out at the beginning of the year and we have now completed the first NHS tender for RESORBA®'s range of products, in line with our stated strategy. We expect the outcome of this first tender toward the end of the year. As a consequence of the RESORBA® acquisition, more of our Group revenues are now Euro denominated. The Group has hedged to protect profitability and, although underlying sales remain healthy, the consequent weakening of the currency could affect our headline revenue number on translation into sterling.

Elsewhere in the Group, our ActivHeal® range continues to perform well and the de-stocking effect that we experienced with one of our partners for silver alginate is now behind us. In our foam business, the targeted H2 launch of trilaminate foam dressings remains on track. However, as discussed in our Preliminary Results, 2012 foam revenues are expected to be impacted by the non-repetition of a large, roll-stock launch order in 2011, combined with our continuing strategy of focusing on higher margin business.

The effect of the expected reduction in foam revenues, together with the likely Euro impact, is that we anticipate full year Group revenues will be below expectations but with a negligible effect on profitability.

In conclusion, whilst global economic conditions remain challenging, the Board is pleased to confirm that we expect profitability for the full year 2012 to be in line with current market forecasts. The long term prospects for the Group remain excellent and we look forward to the coming months with confidence."

- ends -

First impressions look impressive with todays results, now we wait and see what the market thinks.

A buy rec in this weeks IC . shares look cheap on a discount-to-sector forward PE ratio of 14 times. Buy. Im not invested here.

Canaccord Genuity Initiates/Starts Buy TP 93p

Gone long here on AMS. Been waiting for this for a while. Now bouncing off support on gap after last results. Got plenty of broker support and outlook was pretty bullish. Worth a look.

Looks cheap forward P/E of just over
12 going into 2013.

Advanced Medical Solutions Group PLC

FORECASTS 2012 2013
Date Rec Pre-tax (£) EPS (p) DPS (p) Pre-tax (£) EPS (p) DPS (p)

Arden Partners
15-10-12 BUY 12.80 5.28 0.54 14.50 5.84 0.63
Peel Hunt
12-10-12 BUY 12.32 5.03 0.50 13.06 5.34 0.54
FinnCap
12-10-12 HOLD 12.10 5.70 0.50 14.00 6.90 0.50
Shore Capital
05-10-12 HOLD 12.10 5.10 0.60 14.80 5.90 0.70
Investec Securities
05-10-12 BUY 12.80 5.20 0.50 14.80 6.00 0.60
N+1 Brewin
04-10-12 HOLD 11.90 4.80 0.50 13.10 5.20 0.60
N+1 Singer
25-09-12 BUY 12.30 5.10 0.60 14.40 5.90 0.60
Canaccord Genuity Ltd
20-09-12 BUY 12.43 5.01 0.50 14.12 5.23 0.50
Nomura Code
13-09-12 BUY 12.80 5.32 0.51 14.40 5.69 0.57
Seymour Pierce
02-07-12 BUY 12.30 5.10 14.20 5.50
Numis Securities Ltd
22-06-12 BUY 12.90 5.45 0.54 15.20 6.42 0.65

2012 2013
Pre-tax (£) EPS (p) DPS (p) Pre-tax (£) EPS (p) DPS (p)
Consensus 12.43 5.19 0.52 14.13 5.81 0.58
1 Month Change -0.00 0.08 -0.01 -0.10 0.07 -0.02
3 Month Change -0.02 0.08 -0.00 -0.07 0.08 -0.03


GROWTH
2011 (A) 2012 (E) 2013 (E)
Norm. EPS 10.79% 24.48% 11.92%
DPS % -0.19% 10.30%

INVESTMENT RATIOS
2011 (A) 2012 (E) 2013 (E)

EBITDA £7.78m £15.54m £17.21m
EBIT £6.40m £12.45m £14.44m
Dividend Yield 0.73% 0.73% 0.80%
Dividend Cover 7.95x 9.91x 10.06x
PER 17.26x 13.86x 12.39x
PEG 1.60f 0.57f 1.04f
Net Asset Value PS 5.97p 36.15p 41.26p

As per above.....

Trading Update

Hmm, sp taken a hefty knock, not sure that it is entirely justified but there are no prisoners taken in this sector.

positive rns yesterday, see what trading update end june brings

Interim results for the six months ended 30 June 2015.

Advanced Medical Solutions is highly rated and deservedly so: great results!

New research note at http://tinyurl.com/nmr95ut

An epic fortnight for results and updates from AIM, in which Advanced Medical Solutions is also featured. See more at http://tinyurl.com/ovjm7se